Stem Cell Research & Therapy (Sep 2022)

Characterizing the secretome of licensed hiPSC-derived MSCs

  • Yolande F. M. Ramos,
  • Tobias Tertel,
  • Georgina Shaw,
  • Simon Staubach,
  • Rodrigo Coutinho de Almeida,
  • Eka Suchiman,
  • Thomas B. Kuipers,
  • Hailiang Mei,
  • Frank Barry,
  • Mary Murphy,
  • Bernd Giebel,
  • Ingrid Meulenbelt

DOI
https://doi.org/10.1186/s13287-022-03117-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Although mesenchymal stromal cells (MSCs) from primary tissues have been successfully applied in the clinic, their expansion capabilities are limited and results are variable. MSCs derived from human-induced pluripotent stem cells (hiMSCs) are expected to overcome these limitations and serve as a reproducible and sustainable cell source. We have explored characteristics and therapeutic potential of hiMSCs in comparison to hBMSCs. RNA sequencing confirmed high resemblance, with average Pearson correlation of 0.88 and Jaccard similarity index of 0.99, and similar to hBMSCs the hiMSCs released extracellular vesicles with in vitro immunomodulatory properties. Potency assay with TNFα and IFNγ demonstrated an increase in well-known immunomodulatory genes such as IDO1, CXCL8/IL8, and HLA-DRA which was also highlighted by enhanced secretion in the media. Notably, expression of 125 genes increased more than 1000-fold. These genes were predicted to be regulated by NFΚB signaling, known to play a central role in immune response. Altogether, our data qualify hiMSCs as a promising source for cell therapy and/or cell-based therapeutic products. Additionally, the herewith generated database will add to our understanding of the mode of action of regenerative cell-based therapies and could be used to identify relevant potency markers.

Keywords